for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PTC Therapeutics, Inc.

PTCT.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
18.29
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
61.63
Market Cap (MIL)
3,032.24
Forward P/E
-13.78
Dividend (Yield %)
--

Next Event

Q4 2019 PTC Therapeutics Inc Earnings Release

Latest Developments

More

PTC Therapeutics Announces FDA Grants Priority Review To Risdiplam For The Treatment Of Spinal Muscular Atrophy

PTC Therapeutics Posts Qtrly Loss Per Share Of $1.06

PTC Therapeutics's presents positive data on spinal muscular atrophy drug

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

Industry

Biotechnology & Drugs

Contact Info

100 Corporate Ct

+1.908.2227000

https://www.ptcbio.com/

Executive Leadership

Michael Schmertzler

Independent Chairman of the Board

Stuart W. Peltz

Chief Executive Officer, Director

Emily Hill

Principal Financial Officer, Treasurer

Marcio Silva De Souza

Chief Operating Officer

Mark Elliott Boulding

Executive Vice President, Chief Legal Officer

Key Stats

1.82 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.3K

2019(E)

0.3K
EPS (USD)

2016

-4.170

2017

-2.020

2018

-2.750

2019(E)

-3.572
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.21
Price To Book (MRQ)
4.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
47.19
LT Debt To Equity (MRQ)
44.17
Return on Investment (TTM)
-18.74
Return on Equity (TTM)
-16.65

Latest News

Latest News

BRIEF-PTC Therapeutics Announces FDA Grants Priority Review To Risdiplam For The Treatment Of Spinal Muscular Atrophy

* PTC THERAPEUTICS ANNOUNCES FDA GRANTS PRIORITY REVIEW TO RISDIPLAM FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY

BUZZ-PTC Therapeutics: Jumps on deal to buy Agilis Biotherapeutics

** Drug developer's shares up nearly 9 pct at $40.07 in early trading on Friday

BRIEF-PTC Therapeutics Reports Q1 Loss Per Share $0.46

* PTC THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial

* PRELIMINARY CLINICAL DATA FROM FIREFISH TRIAL IN TYPE 1 SMA PATIENTS PRESENTED AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

BRIEF-PTC Therapeutics Prices Public Offering Of Common Stock At $27.04 Per Share​

* PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-PTC Therapeutics Announces Proposed Public Offering Of Common Stock

* PTC THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ptc Therapeutics Says ‍Firefish Study Of RG7916 In Type 1 Spinal Muscular Atrophy Patients Transitioned Into Pivotal Phase With Dosing First Patient​

* PTC THERAPEUTICS INC - FIREFISH STUDY OF RG7916 IN TYPE 1 SPINAL MUSCULAR ATROPHY PATIENTS TRANSITIONED INTO PIVOTAL PHASE WITH DOSING FIRST PATIENT Source text for Eikon: Further company coverage:

BRIEF-PTC Therapeutics Q4 Revenue $78.0 Million

* TOTAL REVENUES FOR Q4 OF 2017 WERE $78.0 MILLION COMPARED TO $25.2 MILLION IN Q4 OF 2016

BRIEF-Boxer Capital Reports 6 Pct Passive Stake In ‍PTC Therapeutics​

* BOXER CAPITAL, LLC REPORTS 6 PERCENT PASSIVE STAKE IN PTC THERAPEUTICS, INC AS OF JANUARY 16, 2018 - SEC FILING Source text - http://bit.ly/2FkWr0i Further company coverage:

FDA declines to approve PTC's Duchenne drug

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.

FDA declines to approve PTC's Duchenne Muscular Dystrophy drug

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.

PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel

PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded...

FDA panel: PTC Therapeutics Duchenne drug data inconclusive

PTC Therapeutics' experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded...

FDA pours cold water on PTC Therapeutics' Duchenne drug application

PTC Therapeutics Inc has failed to supply persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, the U.S. Food and Drug Administration said on Tuesday, dealing a blow to the company's years-long effort to bring the drug...

BRIEF-PTC Therapeutics files for potential mixed shelf; size not disclosed - SEC filing

* Files for potential mixed shelf; size not disclosed - SEC filing Source text : (http://bit.ly/2xgQ4YT) Further company coverage:

BRIEF-PTC Therapeutics qtrly loss per share $0.44

* Ptc therapeutics - qtrly total revenues $48 million versus $15.6 million; qtrly loss per share $0.44; sees fy translarna net sales $120 million - $140 million

BRIEF-Great Point Partners Llc reports 5.24 percent passive stake in PTC Therapeutics Inc

* Great Point Partners LLC reports 5.24 percent passive stake in PTC Therapeutics Inc as of June 6, 2017 Source text: (http://bit.ly/2rAlBWB) Further company coverage:

BRIEF-PTC Therapeutics announces FDA advisory committee meeting for Ataluren for treatment of nonsense mutation dystrophinopathy

* PTC Therapeutics announces FDA advisory committee meeting for Ataluren for the treatment of nonsense mutation dystrophinopathy

BRIEF-PTC Therapeutics appoints Marcio Souza as chief operating officer

* Appointments of Marcio Souza to chief operating officer and Christine Utter to principal financial officer and treasurer Source text for Eikon: Further company coverage:

BRIEF-PTC enters into credit and security agreement for senior secured term loan facility

* Ptc therapeutics inc- on may 5, entered into a credit and security agreement for a senior secured term loan facility of $60.0 million - sec filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up